Drug Interactions between mibefradil and thiabendazole
This report displays the potential drug interactions for the following 2 drugs:
- mibefradil
- thiabendazole
Interactions between your drugs
thiabendazole mibefradil
Applies to: thiabendazole and mibefradil
In vitro studies indicate that mibefradil inhibits the metabolism of drugs that are substrates of the CYP450 1A2 microsomal pathway. This may result in elevated plasma concentrations of these drugs. The manufacturer reports no pharmacokinetic interaction was observed when theophylline, a known substrate of CYP450 1A2, was studied with mibefradil. However, until specific information is available, observation for altered clinical and laboratory effects is recommended if these agents must be used with mibefradil.
References
- "Product Information. Posicor (mibefradil)." Roche Laboratories PROD (2001):
- Thijssen HH, Flin ois JP, Beaune PH "Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes." Drug Metab Dispos 28 (2000): 1284-90
Drug and food interactions
thiabendazole food
Applies to: thiabendazole
MONITOR: Coadministration with thiabendazole may increase the plasma concentrations of caffeine. The mechanism is thiabendazole inhibition of the CYP450 1A2 metabolism of caffeine. In ten healthy, nonsmoking volunteers, administration of a single 136.5 mg dose of caffeine in combination with a single 500 mg dose of thiabendazole resulted in a nearly 60% increase in the area under the plasma concentration-time curve (AUC) of caffeine compared to administration without thiabendazole. In addition, the half-life of caffeine was increased from 11.9 to 28.6 hours, and oral clearance was reduced by 67% during coadministration with thiabendazole. The formation of paraxanthine from caffeine, which is primarily mediated by CYP450 1A2, was almost completely abolished until after the thiabendazole was cleared from the system.
MANAGEMENT: Patients should be advised that pharmacologic effects of caffeine may be increased during coadministration with thiabendazole.
References
- Bapiro TE, Sayi J, Hasler JA, et al. "Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans." Eur J Clin Pharmacol 61 (2005): 755-61
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.